Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Evaluation of COM701 as Maintenance Therapy for Patients with Relapsed Platinum-Sensitive Ovarian Cancer

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial aims to evaluate the effect of COM701 on survival without disease progression in patients with relapsed platinum sensitive ovarian cancer (PSOC). PSOC refers to ovarian cancer that has returned after initial treatment but still responds to platinum-based chemotherapy. The study will also include patients with fallopian tube cancer or primary peritoneal cancer who have undergone at least two previous rounds of platinum-containing therapy.

The study will assess COM701 as a maintenance treatment, which means it will be given after the main cancer treatment to help keep the cancer from returning. Some participants will receive COM701 while others will receive placebo. The research will measure how long patients remain without disease progression while receiving the maintenance therapy.

The safety of COM701 will be carefully monitored throughout the study by tracking side effects, laboratory test results, vital signs, and heart activity. The trial will also track how long it takes before patients need to start a new cancer treatment.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Randomization

    After you complete your platinum-containing therapy for relapsed platinum sensitive ovarian cancer, you will be randomly assigned to receive either COM701 (a humanised monoclonal antibody against PVRIG) or a placebo (saline injection).

    This assignment happens by chance, similar to flipping a coin, to create comparable groups for the study.

  2. Step 2

    Treatment Administration

    You will receive regular injections of either COM701 or placebo as a maintenance therapy (treatment given to help keep cancer from returning after it has responded to initial treatment).

    The treatment will be administered on a set schedule determined by your doctor, which will continue until your disease progresses or you experience unacceptable side effects.

  3. Step 3

    Monitoring and Assessments

    Throughout the study, you will have regular visits to assess how your cancer is responding to treatment.

    These assessments include imaging scans to measure tumor size according to standard criteria (RECIST 1.1).

    Blood tests, vital signs measurements, and heart monitoring (ECG) will be performed regularly to check for any effects of the treatment.

    Your doctor will monitor you for any side effects or adverse events and rate their severity using a standardized scale (CTCAE 5.0).

  4. Step 4

    End of Treatment

    Your participation in the treatment phase will end if your cancer progresses, you experience unacceptable side effects, or you decide to withdraw from the study.

    If your cancer progresses, your doctor will discuss next treatment options with you, and the study will track the time until you start a new anti-cancer treatment.

  5. Step 5

    Follow-up Period

    After completing treatment, you will enter a follow-up period where your health and cancer status will continue to be monitored.

    The study is expected to run until July 2025, with final data collection completed by February 2026.

Who can join the trial?

5 criteria

  • Has relapsed platinum sensitive epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer (these are types of reproductive system cancers that respond well to platinum-based chemotherapy)
  • Has completed at least 2 previous courses (lines) of platinum-containing therapy (treatments that contain platinum drugs like cisplatin or carboplatin)
  • Has received prior maintenance therapy with bevacizumab (a drug that blocks blood vessel growth) or a PARP inhibitor (a type of targeted therapy) if eligible for these treatments
  • Is able to provide written, informed consent before starting any study procedures
  • Is able, in the investigator's opinion, to comply with all the requirements of the study

Who cannot join the trial?

13 criteria

  • You cannot participate if you have a type of cancer that is not platinum-sensitive ovarian cancer (PSOC).
  • You cannot participate if your cancer has progressed during or within 6 months of your most recent platinum-based chemotherapy treatment.
  • You cannot participate if you have another type of cancer that requires treatment.
  • You cannot participate if you have had certain types of cancer treatments in the recent past, such as immunotherapy or experimental drugs.
  • You cannot participate if you have certain active infections, like hepatitis B, hepatitis C, HIV, or tuberculosis.
  • You cannot participate if you have an autoimmune disease (a condition where your immune system attacks your own body).
  • You cannot participate if you've had an organ transplant and are taking medications to prevent rejection.
  • You cannot participate if you are pregnant or breastfeeding.
  • You cannot participate if you have certain heart problems or uncontrolled high blood pressure.
  • You cannot participate if you have severe liver or kidney problems.
  • You cannot participate if you have a history of certain lung conditions or breathing problems.
  • You cannot participate if you've had a recent major surgery.
  • You cannot participate if you are currently enrolled in another clinical trial.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

COM701 is an experimental medication that works with your immune system to help it recognize and attack cancer cells. It blocks a specific protein that cancer cells use to hide from the immune system. In this study, it is being investigated as a maintenance therapy for ovarian cancer, which means it would be given after other treatments to help keep the cancer from returning.

What is already known about the treatment

COM701 – COM701 is an immune checkpoint inhibitor administered intravenously as a maintenance therapy for relapsed platinum-sensitive ovarian cancer (PSOC). This investigational drug is currently being evaluated in clinical trials to assess its safety and efficacy, with promising early results in the treatment of recurrent ovarian cancer. COM701 works by blocking the PVRIG immune checkpoint pathway, which allows the immune system to better recognize and attack cancer cells by enhancing T-cell activity. It belongs to the class of immunotherapeutic agents that aim to restore anti-tumor immune responses, offering a potential new approach for patients who have responded to platinum-based chemotherapy but experienced cancer recurrence.

Investigated diseases

  • Ovarian Cancer

    A disease where abnormal cells develop in the ovaries, which are female reproductive glands responsible for producing eggs and female hormones. These abnormal cells grow uncontrollably, forming tumors that can invade nearby tissues and organs. As the cancer progresses, it may spread (metastasize) to other parts of the body, such as the pelvis, abdomen, or distant organs. Symptoms often appear only in advanced stages and may include abdominal bloating, pelvic pain, difficulty eating, and frequent urination. The disease typically advances through several stages, with higher stages indicating more extensive spread beyond the ovaries.

  • Recurrent Ovarian Cancer

    A condition where ovarian cancer returns after a period of remission following initial treatment. The cancer may recur in the same location as the original cancer or in other areas of the body. Recurrence can happen months or years after the initial treatment is completed. Each recurrence may be more difficult to control than the previous occurrence, as cancer cells can develop resistance to previously effective treatments. Symptoms of recurrent ovarian cancer are similar to those of the initial disease and may include abdominal pain, bloating, and changes in bowel or bladder habits.

Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase ITrial ID2025-521125-33-00Protocol codeCPG-01-201Estimated enrolment60 patientsSponsorCompugen Ltd.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.